Jennifer Zonderman - BioPorto VP Commercialization
| BIOPOR Stock | DKK 1.62 0.01 0.61% |
Insider
Jennifer Zonderman is VP Commercialization of BioPorto
| Phone | 45 45 29 00 00 |
| Web | https://bioporto.com |
BioPorto Management Efficiency
The company has return on total asset (ROA) of (0.4077) % which means that it has lost $0.4077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8803) %, meaning that it generated substantial loss on money invested by shareholders. BioPorto's management efficiency ratios could be used to measure how well BioPorto manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter Kristensen | Genmab AS | 45 | |
| Judith Klimovsky | Genmab AS | 63 | |
| Jonathan Peacock | Genmab AS | 61 | |
| Danilo Verge | Zealand Pharma AS | N/A | |
| Mns Barsne | Ambu AS | N/A | |
| Pernille Erenbjerg | Genmab AS | 52 | |
| Henriette Wennicke | Zealand Pharma AS | N/A | |
| Deirdre Connelly | Genmab AS | 59 | |
| Paolo Paoletti | Genmab AS | 68 | |
| Anthony Pagano | Genmab AS | 45 | |
| Peter Ros | Genmab AS | N/A | |
| Christina Bredal | Zealand Pharma AS | 38 | |
| Daniel Bruno | Genmab AS | 39 | |
| Lani Morvan | Zealand Pharma AS | N/A | |
| Michael Bauer | Genmab AS | 55 | |
| Britt Jensen | Ambu AS | 50 | |
| Rolf Hoffmann | Genmab AS | 60 | |
| Birgitte Stephensen | Genmab AS | 59 | |
| Mads Kronborg | Zealand Pharma AS | N/A | |
| Steven Block | Ambu AS | 60 | |
| Judith MD | Genmab AS | 65 | |
Management Performance
| Return On Equity | -0.88 | |||
| Return On Asset | -0.41 |
BioPorto Leadership Team
Elected by the shareholders, the BioPorto's board of directors comprises two types of representatives: BioPorto inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioPorto. The board's role is to monitor BioPorto's management team and ensure that shareholders' interests are well served. BioPorto's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioPorto's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Bird, Chief Officer | ||
| Neil CPA, Ex CFO | ||
| Jennifer Zonderman, VP Commercialization | ||
| Lars Uttenthal, Chief Officer | ||
| Gry Larsen, G Counsel | ||
| Nis Kruse, Ex APAC | ||
| Anthony Pare, Chief Officer |
BioPorto Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioPorto a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.88 | |||
| Return On Asset | -0.41 | |||
| Profit Margin | (2.50) % | |||
| Operating Margin | (2.82) % | |||
| Current Valuation | 753.23 M | |||
| Shares Outstanding | 334.68 M | |||
| Shares Owned By Insiders | 19.84 % | |||
| Shares Owned By Institutions | 8.60 % | |||
| Price To Earning | (16.82) X | |||
| Price To Book | 9.22 X |
Pair Trading with BioPorto
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioPorto position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioPorto will appreciate offsetting losses from the drop in the long position's value.Moving together with BioPorto Stock
The ability to find closely correlated positions to BioPorto could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioPorto when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioPorto - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioPorto to buy it.
The correlation of BioPorto is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioPorto moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioPorto moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioPorto can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in BioPorto Stock
BioPorto financial ratios help investors to determine whether BioPorto Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioPorto with respect to the benefits of owning BioPorto security.